Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 22, 2024

https://www.globenewswire.com/news-release/2024/05/22/2886839/0/en/Connect-Biopharma-Presents-Late-Breaking-Abstract-at-the-American-Thoracic-Society-2024-International-Conference-on-the-Positive-Rademikibart-Data-from-its-Global-Phase-2b-in-Patie.html

SAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq:CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.